Inventia Healthcare Limited has recalled 11,460 bottles of Chlorthalidone 25 mg tablets due to a failure to meet dissolution specifications, according to the Food and Drug Administration (FDA). The voluntary recall, initiated June 5, affects lots distributed by Rising Pharma Holdings Inc. that may not break down correctly in the human body, potentially impacting drug efficacy for patients treating hypertension and fluid retention.
Which Chlorthalidone Lots Are Recalled?
The FDA enforcement report identifies two specific lots of Chlorthalidone Tablets USP, 25 mg, subject to the recall. Affected products include 100-count bottles under lot number RISA24001 and 1,000-count bottles under lot number RISB24002. Both batches carry an expiration date of April 2027. According to federal records, these units were distributed nationwide by the New Jersey-based firm Rising Pharma Holdings Inc.
Dissolution testing is a standard quality control procedure that measures the rate at which a solid dosage form, such as a tablet, releases its active ingredient into a solution. If a drug fails this test, it may not be absorbed by the body in the therapeutic range intended by the manufacturer.
Why Do Manufacturing Dissolution Issues Occur?
Dissolution failures often stem from variations in the manufacturing process, such as excessive compression force during tableting or the use of binding agents that do not perform as expected under specific stability conditions. While the FDA has not yet assigned a formal classification to this recall, failure to meet dissolution specs is a common trigger for pharmaceutical recalls in the United States.
Pro Tip: How to Check Your Medication
If you have a bottle of Chlorthalidone, check the label for the manufacturer and lot number. If it matches RISA24001 or RISB24002, contact your pharmacist. Do not stop taking your blood pressure medication abruptly, as sudden cessation can lead to dangerous spikes in blood pressure or other cardiovascular complications.
Future Trends in Pharmaceutical Quality Oversight
The pharmaceutical industry is seeing an increase in oversight regarding drug stability and manufacturing consistency. According to the FDA’s Center for Drug Evaluation and Research, manufacturers are increasingly required to provide more granular data on how generic drugs maintain chemical stability throughout their shelf life. This trend suggests that as analytical chemistry becomes more precise, regulatory bodies may detect minor manufacturing deviations that were previously overlooked.
Frequently Asked Questions
- What should I do if I have the recalled medication? Consult your pharmacist or doctor immediately. They can verify if your specific supply is affected and provide guidance on a safe replacement.
- Is it safe to keep taking the tablets until I get a refill? The FDA advises that patients should not discontinue prescribed medication without speaking to a medical professional, as the risks of stopping blood pressure treatment may outweigh the risks of the dissolution issue.
- Where can I find updates on this recall? You can track the status of this recall through the FDA Enforcement Report database using the event ID 99136.
Are you concerned about how manufacturing recalls affect your medication access? Share your questions or experiences in the comments section below, and subscribe to our health newsletter for the latest updates on pharmaceutical safety and regulatory alerts.